Skip to main content

Table 2 Clinical characteristic of 16 P. jiroveci PCR-positive patients and 64 age and sex matched PCR-negative controls.

From: Detection of PneumocystisDNA in samples from patients suspected of bacterial pneumonia- a case-control study

  PCR-positive patients PCR-negative patients p-value
N 16 64  
Age, years 73 (53–78) 71 (51–78)  
Male / female 6 / 10 24 / 40  
Dead within one-month 7 (44%) 9 (14%) p = 0.014
Diagnosis (%)    
Bacterial pneumonia (verified) 3 (19%) 13 (20%)  
Pneumonia, pathogen not identified 6 (39%) 31 (48%)  
Acute bronchitis 5 (31%) 12 (19%)  
Lung malignancy 0 2 (3%)  
Cardiac disease 1 (6%) 4 (6%)  
Other 1 (6%) 3 (5%)  
Concurrent diseases (%)    
Unknown/None 1 (6%) 32 (50%)  
COPD 10 (63%) 13 (20%)  
Malignancy 1 (6%) 4 (6%)  
Lymphoma and bone marrow-transplant 1 (6%) 1 (2%)  
NYHA III/IV 1 (6%) 13 (20%)  
NYHA III/IV and COPD 1 (6%) 1 (2%)  
Chronic renal failure 0 1 (2%)  
Renal transplantation and malignancy 1 (6%) 0  
Total number with concurrent diseases 15 (94%) 32 (50%) p = 0.004
Immunosuppressive therapy (%)    
None 4 (25%) 56 (87%)  
Steroids alone 10 (63%) 7 (11%) p < 0.001
Chemotherapy alone 0 1 (2%)  
Chemotherapy and steroids 1 (6%) 0  
Azathioprine and steroids 1 (6%) 0  
Total number receiving steroids 12 (75%) 8 (13%)  
Corticosteroid dosea 37,5 (8,8–58,8) 7.5 (5–27,5) p = 0.026
Duration of corticosteroid therapy, weeks (range) 66 (1–102) 8 (1–42) p < 0.001
  1. All values are Median (25–75 percentiles). a Corticosteroid dose in daily equivalents of prednisone in milligrams at time of diagnosis. COPD: Chronic obstructive pulmonary disease. NYHA: New York Heart Association.